that the child be able to carry out daily activities and prevent joint deformities. Children with CP have difficulties with mobility and posture. Occupational therapists often assess and prescribe seating equipment and wheelchairs. An appropriate wheelchair will stabilize the body so the child can use their arms for other activities. Wheelchairs therefore enhance independence. Accessible housing may assist some people with cerebral palsy, particularly wheelchair users. Assistive technologies used during sleep to position the body to prevent painful hip migration are called 'sleep positioning systems'. Studies on their effectiveness are of poor quality. Medication Various oral and injectable medication have been used to treat cerebral palsy and its associated comorbid conditions. They include botulinum toxin, benzodiazepines, baclofen, dantrolene, tizanidine, cyclobenzaprine, and phenol. Botulinum toxin injections are given into muscles that are spastic or sometimes dystonic, the aim being to reduce the muscle hypertonus that can be painful. A reduction in muscle tone can also facilitate bracing and the use of orthotics. Both lower extremity and upper extremity muscles are injected. Botulinum toxin is focal treatment, meaning that a limited number of muscles can be injected at the same time. The effect of the toxin is reversible and a reinjection may be needed every 4–6 months. In children it decreases spasticity and improve range of motion and thus has become commonly used. Botulin toxin has been used in CP treatment for around two decades and can be recommended for children above the age of two. Two systematic reviews published in 2010 and 2020 found that there is high level evidence in the use of botulinum toxin as an add on therapy to occupational therapy among other physical therapies modalities in order to manage spasticity in the arms of children with cerebral palsy. However, there is no strong research associated with the use of botulinum toxin in the management of spasticity in the legs or improving gait compared to casting. More evidence related to the frequency and dosage of injections as it relates to long-term outcomes is needed in order to support or refute the use of botulinum toxin in the management of lower limb spasticity in children with cerebral palsy. Dosages of botulinum toxin have been based on expert opinion rather than evidence-based practices. The dosages recommended have recently been reduced to reduce severe side-effects including becoming sensitive to the botulin toxin and developing an allergic response. Higher risks have been